---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032644"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2026-08-13T12:01:03+00:00"
generated_at: "2026-08-13T12:05:17.073822+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics Q1 net loss $15.8M, $13.5M IPR&D impairment

## Summary
- Net loss $15.8M ($0.91/share) vs $3.4M ($0.21) YoY; includes $13.5M impairment of GTx-101/102 IPR&D.
- Cash $22.2M as of Aug 11, 2026; runway through end of 2028; $10M private placement announced.
- FDA Type A meeting minutes received; CRL items are CMC/non-clinical, no clinical safety/efficacy issues.
- Dual-source manufacturing: tech transfer to second U.S. CMO underway; NDA resubmission timing depends on site readiness.

## SEC filing metadata
- accession: 0001140361-26-032644
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2026-08-13T12:01:03+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/0001140361-26-032644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032644
- JSON: https://secwatch.observer/filing/0001140361-26-032644.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.